In:
European Journal of Haematology, Wiley, Vol. 80, No. 1 ( 2008-01), p. 1-9
Kurzfassung:
Involvement of the central nervous system (CNS) in multiple myeloma (MM) is very uncommon; it has been observed in approximately 1% of the MM patients. This review summarizes the clinical and laboratory characteristics and treatment modalities of 109 patients with CNS myelomatosis (CNS MM) reported in the literature. CNS MM has a wide spectrum of neurological symptoms and signs. No guidelines for therapy of CNS MM are available, which has resulted in a large variation in the treatment schedules. Treatment options include intrathecal chemotherapy (IT), systemic chemotherapy (SC), cranial irradiation (CI) or a combination. The prognosis of CNS MM remains poor, with an overall median survival from the time of diagnosis to death of 2.0 months (range 0.1–25 months). Patients who were treated with CI had a significantly ( P = 0.004) longer survival when compared with patients without CI.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2008.80.issue-1
DOI:
10.1111/j.1600-0609.2007.00956.x
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2008
ZDB Id:
2027114-1
